1-2 of 2
Sharon Spence
Close
Sort by
Journal Articles

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MD MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Sharon Spence, Shay Shemesh, Christopher Brooks, PhD, Ivan Bergstein, MD, Janice Chen, PhD, Vanessa Dunn, Peter McDonald, John Mark Sloan, MD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 765.
https://doi.org/10.1182/blood-2018-99-118966
Published: 2018
Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Kendra L. Sweet, MD, Andrew A. Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MDMBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Phyu Aung, MD, Danielle Shubert, Sharon Spence, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Ivan Bergstein, MD, Peter McDonald, Trishna Goswami, MD, John Mark Sloan, MD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1298.
https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298
Published: 2017